Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

Inclusion Criteria: * Males and females 18 years of age or older * Confirmed VWD by 2 of 4 VWD coagulation tests abnormal * A past bleeding history * No hormone, oral contraceptive, estrogen use in past 8 weeks * Willingness to have blood drawn * Willingness to sign informed consent Exclusion Criteria: * Presence of other bleeding disorder, e.g. acquired VWD, thrombocytopenia * Use of estrogens, hormones, oral contraceptives in past 8 weeks * Use of immunomodulatory or experimental drugs or diuretics * Pregnant or lactating women * Past cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis * Past allergic reaction to Neumega or DDAVP * Surgery within the past 8 weeks * Inability to comply with study protocol requirements * Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin, or NSAIDs * Treatment with DDAVP, cryoprecipitate, whole blood, plasma, and plasma derivatives containing FVIII, VWF within 5 days of study